Illumina Inc (ILMN) Financial Statements
Historical financial data — 40 statements covering FY2016–FY2025
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumab...
Illumina Inc's revenue decreased 0.7% year over year, from $4.37B to $4.34B.
Net income increased 169.5% over the same period, from $-1.22B to $850.0M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 81% in total.
Operating cash flow grew 28.9% to $1.08B.
Illumina Inc maintains a healthy net profit margin of 19.6%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2023 | $2.26B+108.2% | $-231.0M | $1.39B | $-152.0M | $115.0M | $11.77B | N/A | $6.55B |
| Q3 FY2023 | $3.38B+49.4% | $-986.0M | $2.07B | $-905.0M | $254.0M | $10.12B | N/A | $5.90B |
| Q1 FY2024 | $1.08B-68.2% | $-126.0M | $667.0M | $-111.0M | $77.0M | $10.04B | N/A | $5.73B |
| Q2 FY2024 | $2.19B+103.3% | $-2.11B | $1.39B | $-1.75B | $157.0M | $6.08B | N/A | $1.44B |
| Q1 FY2025 | $1.04B-52.4% | $131.0M | $683.0M | $164.0M | $240.0M | $6.18B | N/A | $2.37B |
| Q2 FY2025 | $2.10B+101.7% | $366.0M | $1.38B | $378.0M | $474.0M | $6.09B | N/A | $2.26B |
| Q3 FY2025 | $3.18B+51.6% | $516.0M | $2.11B | $606.0M | $758.0M | $6.18B | N/A | $2.38B |
| Q1 FY2026 | $1.09B-65.7% | $134.0M | $721.0M | $209.0M | $289.0M | $6.56B | N/A | $2.68B |
Balance Sheet Summary (Latest Period)
Total Assets
$6.64B
Total Liabilities
$3.92B
Total Equity
$2.72B
Cash & Equivalents
$215.0M
Total Debt
N/A
Current Assets
$3.29B
Current Liabilities
$1.58B
Retained Earnings
$-392.0M